Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
β-caryophyllene for inflammation in type 2 diabetes and acute coronary syndrome
IRCT20180103038199N20Phase 3Recruiting
- Sponsor
- Mashhad University of Medical Sciences
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of beta-caryophyllene in type 2 diabetes mellitus (T2DM) and acute coronary syndrome (ACS), sponsored by Mashhad University of Medical Sciences. Started May 2026; status: recruiting.
02
Drugs
beta-caryophyllene
03
Conditions
type 2 diabetes mellitus (T2DM)acute coronary syndrome (ACS)
Beyond the preview
Go deeper on IRCT20180103038199N20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180103038199N20.